Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Characteristics during hospital stay

From: Systemic infection and microglia activation: a prospective postmortem study in sepsis patients

 Control N = 15Sepsis N = 16p-value
Hospital admission
 Reason for admission. N (%)
  Cardiac9 (60.0)2 (12.5) 
  Infection07 (43.8) 
  Elective surgery3 (20.0)2 (12.5) 
  Emergency surgery01 (6.3) 
  Other medical3 (20.0)4 (25.0) 
 Ward. N (%)
  Cardiology5 (33.3)0 
  Intensive care unit2 (13.3)15 (93.8) 
  Emergency room2 (13.3)0
  Internal medicine2 (13.3)1 (6.3) 
  Other4 (26.6)0 
Complications during hospital stay
 AKI. N (%)1 (6.7)10 (62.5)< 0.001
 ARDS. N (%)1 (6.7)7 (43.8)0.013
 Thrombocytopenia. N (%)1 (6.7)8 (50)0.010
 DIC. N (%)012 (75)< 0.001
 Shock N (%)10 (66.7)16 (100)0.018
Septic016 (100) 
Cardiogenic8 (53.3)0 
Obstructive1 (6.7)0 
Hypovolemic1 (6.7)0 
Interventions during hospital stay
 Mechanical ventilation. N (%)2 (13.3)12 (75.0)0.001
 RRT. N (%)07 (43.8)0.007
 Surgery. N (%)3 (20.0)7 (43.8)0.152
 Resuscitation. N (%)9 (60.0)6 (37.5)0.186
 Vasoactive medication3 (20.0)15 (81.3)< 0.001
Infection and treatment
 At least 1 positive culture. N (%)7 (46.7)16 (100.0)0.001
Bacteremia08 (50.0) 
Abdomen08 (8.0) 
Respiratory tract3 (20.0)7 (43.8) 
Urogenital tract4 (26.7)2 (12.5) 
Peripheral02 (12.5) 
Cardiac01 (6.3) 
 N different microorganisms. Median (IQR)0 (0.0–1.0)1.5 (1.0–2.0)0.003
 Patients with antimicrobial therapy. N (%)5 (33.3)13 (81.3)0.011
 Defined daily doses. Median (IQR)0 (0.0–0.7)2.2 (1.0–3.3)0.002
Death
 Cause of death. N (%)
  Cardiac/hemodynamic14 (93.3)2 (12.5)< 0.001
  Respiratory1 (6.7)0 
  MOF013 (81.3) 
  Other01 (6.3) 
 Hospital stay, days. Median (IQR)2.2 (1.2–8.2)5.9 (2.1–14.6)0.142
 Active malignancy at death. N (%)04 (25.0)0.101
 Hours between death and autopsy. Median (IQR)21.7 (11.8–27.3)18.4 (11.3–33.2)0.608
  1. AKI acute kidney injury, ARDS acute respiratory distress syndrome, APACHE IV acute physiology and chronic health evaluation, DIS disseminated intravascular coagulation, MOF multiple organ failure, RRT renal replacement therapy, SOFA sequential organ failure assessment